Clinical Trials Directory

Trials / Unknown

UnknownNCT02371096

Comparative Pharmacokinetic Trial of RGB-03 and MabThera

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
Sponsor
Gedeon Richter Plc. · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers

Summary

Pharmacokinetic properties, efficacy, safety and tolerability of RGB-03 and MabThera will be compared in patients suffering from Rheumatoid Arthritis.

Conditions

Interventions

TypeNameDescription
DRUGMabThera (rituximab)
DRUGRGB-03

Timeline

Primary completion
2016-06-01
First posted
2015-02-25
Last updated
2015-02-25

Source: ClinicalTrials.gov record NCT02371096. Inclusion in this directory is not an endorsement.

Comparative Pharmacokinetic Trial of RGB-03 and MabThera (NCT02371096) · Clinical Trials Directory